Insulin Signalling-Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance
A protein marker in blood may predict which multiple myeloma patients won't respond to standard treatment, opening paths to personalized therapy choices.
This study identified that IFITM1, induced by insulin receptor signaling, is significantly elevated in symptomatic multiple myeloma vs. MGUS/smoldering MM and correlates with inferior outcomes after autologous stem cell transplant and bortezomib-based therapy. The findings suggest IFITM1 as a novel biomarker and potential therapeutic target for bortezomib-resistant MM.
What the study was
- Study design
- Translational mechanistic study (patient cohorts + in vitro)
- Population
- Multiple myeloma patients (symptomatic MM vs. MGUS/SMM) and MM cell lines
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Journal of Cellular and Molecular Medicine
Why it surfaced
Bortezomib resistance in MM is a significant clinical problem; IFITM1 as a new prognostic biomarker and resistance mechanism is a potentially actionable finding if validated in larger cohorts. Score limited by mixed human/in vitro design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.